Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing advanced drug delivery systems and telemedicine solutions that enhance patient care and compliance. Founded in 2018, Vivera Pharmaceuticals, Inc. operates out of Newport Beach, US, focusing on innovative biopharmaceutical solutions.

The company has engaged in 2 deals to date, with the most recent funding round occurring on November 25, 2020. CEO Paul Edalat co-founded the company, bringing his expertise in healthcare innovation. Vivera Pharmaceuticals, Inc. specializes in innovative biopharmaceutical and medical technology solutions, focusing on enhancing drug delivery systems and telemedicine applications.

The company's flagship product, the TABMELT sublingual drug delivery system, allows for efficient administration of medications, providing a non-invasive route that enhances patient compliance. Complementing this is the ZICOH device, an intelligent, dose-controlled electronic prescription dispensing system designed to improve communication throughout the pharmaceutical supply chain and ensure adherence to prescribed treatments. Additionally, Vivera's MDZone serves as a portable telemedicine station, facilitating remote clinical services and expanding access to healthcare for underserved populations. Their products target multiple geographical markets, including the United States and the United Kingdom, with ongoing efforts to expand their reach further across global healthcare systems.

Vivera Pharmaceuticals generates revenue through the sale of its proprietary products and licensing agreements. The company operates primarily on a business-to-business model, partnering with healthcare providers, pharmacies, and telehealth platforms to distribute its innovative solutions. Transactions typically involve direct sales of devices like the TABMELT and ZICOH, which are supplied to healthcare facilities and practitioners who utilize these technologies to enhance patient care. Vivera's pricing structure is designed to reflect the advanced functionalities of its products, enabling healthcare providers to adopt efficient, compliant treatment protocols.

The company also engages in partnerships that facilitate broader access to its technologies, further solidifying its presence in the healthcare ecosystem. Vivera Pharmaceuticals, Inc. is actively pursuing the development of new products designed to enhance drug delivery and telehealth capabilities. Recent funding received in November 2020 from JR Dallas Wealth Management is part of a larger EUR 440 million equity and debt funding, which will support the expansion of their product line and market reach.

The company aims to introduce additional innovative healthcare solutions and expand into new markets, specifically targeting the United States and the United Kingdom for significant growth by 2023.